FOLH1 and neoplasm: [177Lu]Lu-PSMA-ALB-56 was injected in 10 patients with mCRPC (3360 ± 393 MBq) and showed normalized absorbed doses up to 2.3-fold higher in tumor lesions (6.64 ± 6.92 Gy/GBq) than conventional 177Lu-labeled PSMA ligands.